IASO Bio Publicizes NMPA’s IND Acclaim for Equecabtagene Autoleucel in Second-Line Therapy of Just a few Myeloma, Industry Info
Business new tamfitronics /PRNewswire/ — IASO Bio, a biopharmaceutical firm engaged in discovering, constructing, manufacturing and advertising and marketing modern cell therapies and antibody products, on the present time offered that China National Clinical Products Administration (NMPA) has authorized the Investigational Unusual Drug (IND) utility for Equecabtagene Autoleucel (IASO Bio R&D code: CT103A), a self-developed […]